Schizophrenia
2,906
185
220
2,020
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
668 trials with published results (23%)
Research Maturity
2020 completed trials (70% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
7.2%
210 terminated out of 2906 trials
90.6%
+4.1% vs benchmark
27%
790 trials in Phase 3/4
33%
668 of 2020 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2020 completed trials
Clinical Trials (2906)
Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine
Examining the Efficacy of a Virtual Reality Cognitive Remediation Program for People Living With Psychosis
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Venous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Enhancing Veteran-Clinical Collaboration in VA PRRCs
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers
Studies of Frontal Lobe Brain Functioning in Schizophrenia
Risk of Breakthrough Symptoms With Long-Acting Injectable Medications
Effect of Curcumin Add-On Therapy on Quality of Life and IL-1β Levels in Patients With Schizophrenia
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine
Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia
52-week Open Label Safety-Tolerability Study